Aeterna Zentaris Inc. (NASDAQ:AEZS) shares traded up 2.3% on Thursday . The stock traded as high as $3.52 and last traded at $3.51, with a volume of 102,717 shares. The stock had previously closed at $3.43.

Several brokerages recently commented on AEZS. Maxim Group reaffirmed a “buy” rating and set a $11.00 target price on shares of Aeterna Zentaris in a report on Wednesday, June 15th. Canaccord Genuity reaffirmed a “buy” rating and set a $9.00 target price (down previously from $13.00) on shares of Aeterna Zentaris in a report on Monday, April 4th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $12.00 target price on shares of Aeterna Zentaris in a report on Sunday, July 10th.

The stock’s 50 day moving average price is $3.45 and its 200-day moving average price is $3.45. The firm’s market capitalization is $34.19 million.

Aeterna Zentaris Inc is a Canada-based specialty biopharmaceutical company engaged in developing treatments in oncology, endocrinology and women’s health. The Company has three wholly owned direct and indirect subsidiaries: AEZS GmbH, based in Frankfurt, Germany, Zentaris IVF GmbH, a direct wholly owned subsidiary of AEZS Germany based in Frankfurt, Germany, and Aeterna Zentaris, Inc Its drug development efforts are focused on two compounds, zoptarelin doxorubicin and Macrilen, which are in clinical development, and on two oncology compounds (an Erk inhibitor and Luteinizing Hormone-Releasing Hormone-disorazol Z product candidates), which are in pre-clinical development.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.